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Thesis Summary
Introduction
The aim of this study was to assess the effect of deprivation on pathological 
prognostic Indicators in breast cancer and to find a population of patients 
with breast cancer who are unlikely to have axillary métastasés and therefore 
be spared axillary clearance.
It is well recognised that patients from deprived areas with breast cancer 
have a poorer outcome. The reasons for this are unclear. Some studies have 
found that patients from deprived areas are more likely to have oestrogen 
receptor negative tumours, which have a poorer prognosis. Others have 
found no relation between deprivation and pathological prognostic factors 
and suggest poorer outcome may be due to late presentation or impaired 
host responses secondary to, for example, co-morbidity, genetic, diet or 
environmental factors.
Axillary clearance provides Information for staging and prognosis and may 
also provide local control and even cure as well as aiding in the decision to 
give adjuvant treatment. However it carries with It significant morbidity such 
as lymphoedema, paraesthesia and reduced shoulder mobility.
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Recently much work has been done into the role of sentinel node biopsy as a 
means of assessing the axilla for métastasés, but there Is still a false negative 
result of up to 10% with this procedure. It has been found that sentinel node 
biopsy is more effective in patients at low risk of axillary spread.
It has been found in other studies that the incidence of nodal métastasés in 
patients with tumours of 10mm or less is low. Some studies of tumours of 
5mm or less have had an Incidence of axillary métastasés of 0% and some 
suggest abandoning axillary clearance In these patients. Other studies of 
tumours up to 10mm have had as many as 27% with positive nodes.
We wanted to find out whether deprivation In the Glasgow area had any 
effect on tumour pathology and lymph node spread which may account for 
poorer outcome. We also wanted to find out which patients with small 
tumours were least likely to have nodal spread, and therefore be spared 
axillary clearance or provide a target population for assessment with sentinel 
node biopsy.
Method
The data was collected prospectively from five hospitals in the Glasgow area 
and included all patients who had breast cancers operated on between
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October 1995 and March 2001. They included both screen detected and 
symptomatic patients.
Patients were separated Into three groups -  affluent, intermediate and 
deprived according to the Carstairs index of deprivation at the time of 
diagnosis. This is a deprivation score based on area of residence using census 
data. The influence of deprivation on the pathological size of the tumour, 
histological grade, ER status, axillary node status and Nottingham prognostic 
index (NPI) were examined. Deprivation data was available for 3251 patients.
In total there were 666 patients who had tumours of 10mm or less. We 
excluded those who had less than 4 axillary nodes excised when looking at 
the incidence of nodai métastasés in these patients as it was assumed that 
some might not have had their axillae accurately assessed. Those with 
ungraded tumours were also excluded leaving 613 patients in this part of the 
study. 64% were screen detected. Deprivation scores were available for 608 
of these patients.
The pathological variables we examined were size, which we split into those 
of 5mm or less (Tla) and those of 6-lOmm (Tib). We also looked at size as a 
continuous variable. The other variables were histological grade, the presence 
of lymphovascular invasion and ER status.
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Results
When we looked at the effect of deprivation on ER status, size, grade, node 
status and NPI the deprived patients were significantly more likely to have 
high grade tumours. 27% of affluent, 30% intermediate and 35% deprived 
had grade 3 tumours (p<0.02). We also found that they had significantly 
larger tumours at operation. 33.3% of affluent, 35.6% of intermediate and 
43.4% of deprived had tumours of greater than 20mm (p<0.001). 
Significantly fewer of them had been screen detected (p<0.01) suggesting 
they are presenting later. Deprived patients were more likely to be ER 
negative (p=0.016). There was no significant relationship between 
deprivation and nodal status. Because deprived patients had larger tumours 
at operation and had a higher incidence of grade 3 tumours, they were 
significantly more at risk according to NPI (p<0.01).
Similar results were seen when we assessed those with tumours of 10mm or
less. We found that patients in the deprived group were significantly more
likely to have higher grade tumours with 11.1% of affluent, 15.4% of
intermediate and 21.7% of deprived patients having grade 3 tumours (p=
0.032). There was a trend for the more deprived patients to have a higher
incidence of ER negative tumours with 11.3%, 17.9% and 19.3% of patients
in the affluent, intermediate and deprived groups having a negative ER status
respectively. This however was not significant (p= 0.073). More patients in
the deprived group had lymphovascular invasion present, 13.9% compared to
10.6% and 10.4% in the intermediate and affluent groups (p= 0.3), however
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there was no relationship between nodal spread and deprivation (p=0.9), nor 
was there any significant difference in NPI between the groups (p=0.3) 
although a higher proportion of the affluent group had a low risk NPI. 
Presumably because size is essentially being removed from the equation.
Of all the patients with tumours of 10mm or less 18.1% of had positive 
nodes. There was a trend for the larger size tumour to have an increased 
incidence of positive nodes with 13.4% of Tla and 19.2% of T ib tumours 
being node positive. This difference was not significant, but when we looked 
at size as a continuous variable It was a significant indicator of nodal spread 
(p<0.001). A higher grade was also a significant indicator of nodal spread 
with 11.4% of grade 1, 21% of grade 2 and 31.3% of grade 3 tumours 
having positive nodes (p<0.001).
We looked at the influence of size within each grade and the trend for the 
larger size tumours to be more likely to have nodal disease is still there In 
grades 1 and 2, but not for the grade 3 tumours. This finding is most likely 
because of the smaller numbers in this group with only 16.2% of patients 
having grade 3 tumours.
The most important indicator of lymph node spread was the presence of 
lymphovascular Invasion. 13.4% of patients with tumours without 
lymphovascular invasion were node positive compared to 54.3% of those 
where lymphovascular invasion was present (p<0.001).
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The influence of lymphovascular invasion within each grade was also 
examined. There was a higher incidence of positive nodes when 
lymphovascular Invasion was present and this was true for each grade. It was 
not significant In the grade 3 group and again this is most likely because of 
the smaller number In this group.
When we looked at ER status, as a single variable, those with ER negative 
tumours were significantly more likely to have axillary métastasés than those 
with ER positive tumours (p=0.038). 16.5% of ER positive tumours and 
25.7% of ER negative tumours were node positive. However, when we 
corrected the ER status for the other three variables with a multivariate 
analysis it was no longer a significant factor.
According to our multivariate analysis the most important predicting indicator 
was lymphovascular Invasion with a greater than five fold increase In risk of 
having positive nodes If lymphovascular invasion was present. Next was 
grade with a relative risk of 1.51 for each step up in grade and then size with 
a relative risk of 1.15 for each millimetre increase in size.
Low risk tumours are those of grade 1 without lymphovascular Invasion. In 
total 9.5% of them were node positive. Of those 5mm or less 5.7% were 
node positive. None of the patients with grade 1 tumours of less than 5mm 
without lymphovascular Invasion had axillary métastasés, although the 
number in this group was very small.
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Conclusion
It would appear that deprived patients are presenting later with bigger, more 
aggressive tumours and fewer have small low risk cancers. This is possibly 
partly due to co morbidity, genetic or environmental factors, but also may be 
due to fewer deprived patients attending for screening.
Although deprived patients with small cancers of 10mm or less were 
significantly more likely to have high grade tumours and had a higher 
incidence of LVI there was no relationship between nodal spread and 
deprivation. This was true even when looking at tumours of all sizes.
We have found that axillary métastasés from tumours of 10mm or less do 
occur. In this study even in those with tumours of 5mm or less the incidence 
of positive nodes was 13.4%. We therefore cannot routinely omit axillary 
clearance In these patients.
Risk of lymph node spread is multifactorial. Patients with small, low grade 
tumours without lymphovascular invasion are least likely to have nodal 
disease. It may be that these patients can provide a target population for 
assessment with sentinel node biopsy prior to the decision to omit clearance.
17
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CHAPTER 1 
Introduction
1.1
Breast cancer incidence and mortality
Breast cancer is the commonest type of cancer in women. 18% of all cancers 
in females are breast malignancies. There are around one miilion new cases 
per year worldwide. ^
In Britain It will affect around 1 in 10 women during their lifetime. Around half 
of these will be in women over the age of 65 with the majority occurring in 
women over 55. It was the most common cause of cancer death in women 
until 1999, but since then there have been more deaths from lung cancer. It 
is the commonest cause of death In women In the 35-54 year old age group 
accounting for 17% of all deaths.^
The incidence of breast cancer has continued to gradually increase over the 
past few decades. There was a steep increase In incidence in the 1980s which 
coincided with the introduction of the breast screening programme and 
reflected an increase in detection rates, (figure 1). Screening aside, the 
incidence of breast cancer In many parts of the world continues to rise 
especially in low risk areas.^ Despite this, however, standardised mortality
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rates are levelling ® In 2003 there were 12,614 female breast cancer
deaths in the UK compared to 15,625 in 1989/
This may be due to a combination of things such as improved treatments and 
the increased detection of smaller, better prognosis tumours from screening. 
Survival Increase may also be explained partly by improvements in 
organisation and delivery of care. ^
105
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Figure 1. Incidence and mortality from breast cancer in Britain at 
introduction of screening. Graph from Brewster D, et al. BMJ 312; 
7031. March 1996.
The reason for the continuing gradual increase in breast cancer is unknown 
and probably multlfactorlal as is the aetiology.
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1.2
Breast Screening
Breast screening was introduced in Scotland in 1988 although was not 
universally available until 1991 and the first round was completed in 1994. 
There are five criteria for any screening programme:
• The condition must be common with serious consequences.
• An identifiable precursor or marker Is required and the screening test has 
to have a high sensitivity and specificity for detecting these.
• Treatment of screen detected disease has a better outcome than that of 
the symptomatic disease.
• The screening test has to be acceptable to the patient.
• The screening programme has to be cost effective.
The first point, the condition must be common with serious consequences, is 
undoubtedly true for breast cancer. As mentioned above it Is the most 
common cancer in women and is responsible for around 12,600 deaths each 
year in Britain.
The precursor, or marker, in breast cancer Is the pre-malignant (carcinoma in 
situ), early invasive and/ or impalpable breast lesion as seen on 
mammography. Mammography is the only tool that has been shown to be 
effective for early detection of these lesions. It has a sensitivity of around 
90% (That Is, the ability to detect disease in those who have it.) and a 
specificity of around 95-99% (The ability to exclude disease in those who do
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not have it .) /  There is no evidence that clinical examination, ultrasonography 
or teaching self examination is effective. ^
Thirdly, the treatment of the screen detected disease should have a better 
outcome than that of the symptomatic disease. Initially critics of breast 
screening felt that It would not reduce mortality. They thought it would 
simply introduce lead time bias (detecting cancers earlier would give the 
impression that women were surviving longer), length time bias (detecting 
slower growing, less lethal cancers) and selection bias (women opting to have 
screening may mainly be from one particular background, for example higher 
socioeconomic status).
As already discussed and as can be seen in figure 1, despite a gradual 
increase in incidence of breast cancer (some of which is due to the 
introduction of screening Itself), mortality from the disease is falling. This, in 
part, is due to breast screening. Several randomised controlled trials have 
shown that mammographie screening can significantly reduce mortality from 
breast cancer In those who attend. Nystrom et al showed In their overview of 
Swedish screening trials a 29% reduction in mortality in women screened 
between the ages of 50 and 69 years of age over a 12 year follow up period. 
There was no significant reduction in mortality In women of 40-49 years 
(mammography is less sensitive in younger age groups) and only marginal 
improvement in those 70-74 years.^° Similar results were seen in a meta­
analysis by Kertilowski et al.^  ^ An early trial from Edinburgh showed only a
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20% reduction in mortality in women over 50 years of age who were 
screened over a 7 year follow up period. Compliance with screening in this 
study, however, was poorer.^^ Over 70% of the target population need to 
attend if mortality is to be reduced significantly.^ In Scotland the uptake for 
screening is around 74% although this varies slightly between health board 
areas and areas of different socioeconomic class.^^
Another positive outcome measure with mammographie screening includes a 
better cosmetic outcome with more breast conservation owing to the finding 
of smaller tumours at mammography.
The screening test obviously has to be acceptable to the target population or 
compliance with the screening will decline and the effect on mortality 
reduced. Mammography is non invasive although can be uncomfortable for 
the patient. The lifetime risk of breast cancer arising from the radiation 
exposure during the screening is minimal . In general mammography is seen 
as an acceptable screening method.
Lastly, the screening programme has to be cost effective. Up until recently, in 
Britain, screening was offered to women between the ages of 50 and 64 and 
was available on a voluntary basis In older age groups. Now women of up to 
70 years of age are being invited routinely although this is not occurring 
everywhere In Scotland as yet. That is, it is offered to women in whom it has 
been shown to be of most benefit with regards to reducing mortality.
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Screening in the younger age groups would increase the cost per life year 
saved. There is no benefit with regards to reduction of mortality by screening 
any more frequently than every 2 years (in an attempt to reduce numbers of 
interval cancers) and this would therefore only reduce cost effectiveness.^^ In 
Britain, women are invited routinely every 3 years. At each screen an oblique 
and craniocaudal view mammogram is taken. This increases the detection 
rate of cancers by 24% and this increased detection rate, in turn, does not 
make it any less cost ef fect ive.As mentioned above, compliance with 
screening has to be over 70% to have a significant effect on mortality and to 
maintain cost effectiveness. Thus it is important that the screening 
programme is adequately organised with accurate patient lists and the target 
population are educated as to the benefits of screening and are encouraged 
to attend.
Also of consideration is the cost to the patient such as anxiety regarding the 
result, risk of false positives and harm of negative biopsies and 
inconvenience. With adequate patient education and a well trained 
multidisciplinary assessment team the overall experience causes little more 
anxiety in screened women than in controls.^
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1.3 
Risk factors
There does not appear to be one single cause of breast cancer. Its aetiology 
is multifactorial, however there are some established and probable risk 
factors for the disease.
1.3.1 Age
The risk of breast cancer increases with age. The incidence roughly doubles 
every 10 years. After the menopause the risk continues to increase, but at a 
slower rate.
1.3.2 Reproductive history
Early onset of menstruation and late menopause are both risk factors. It has 
been found that women who have the menopause before the age of 45 have 
half the relative risk of breast cancer than women who are over 55.^  ^ Factors 
which delay onset of menstruation such as physical activity or produce an 
early menopause such as oophorectomy have a protective effect.
Age at birth of the first child also effects breast cancer risk. Women who are 
nuiliparous or have their first child when they are over the age of 30 have a 
risk double that of those who have a child when they are under the age of 
18.^^  There is no evidence to suggest that abortion either spontaneous or 
induced increases breast cancer r\sk}^ From the above it can be seen that
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greatest risk lies with those who have a longer period of uninterrupted 
menstrual cycles.
1.3.3 Exogenous hormones
Increased exposure to oestrogens is thought to increase breast cancer risk. 
Many studies have shown that women taking or who have taken the oral 
contraceptive pill (OCR) are at an increased risk of breast cancer. In general 
though, the increase in risk compared to those who have never taken the oral 
contraceptive pill is slight and reverts to normal female population risk 10 
years after stopping. It would also appear that breast cancers diagnosed in 
women who have taken the OCR are less advanced than in those who have 
not. It is not known whether this is due to earlier detection, the effects of the 
hormone, or both.
Similarly, hormone replacement therapy (HRT) increases risk and has an 
effect akin to that of delaying menopause one year for each year of therapy
i.e. the risk increases with duration of use. The risk remains elevated for 5 
years after stopping. There does not appear to be any higher mortality from 
breast cancer in women on HRT. As with OCR use cancers detected in women 
who have at some stage taken HRT seem to be less advanced.
1.3.4 Country of residence
There is a wide variation in incidence and mortality rates between different 
countries. The incidence can vary five fold between country around the world.
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In general more westernised countries have a higher incidence and mortality. 
In some Western countries there is greater than 100 cases per 100000 
women compared to 10-15 cases per 100000 women in Asia.^  ^ As previously 
mentioned the rates of breast cancer are increasing and the rate of increase 
is highest in those low risk countries. This may be due in part to marked 
lifestyle changes in these countries over the last 50 years.
Japan has one of the lowest incidences of breast cancer in the world at 
around 20 cases per 100000 population. Low rates here can be partly, but 
not completely explained by the later age of menarche and lower rate of 
nulliparity in Japanese w o m e n . I t  has been shown that when women from 
low risk countries emigrate to a high risk country their offspring will, within 
one or two generations take on the rate of their new country of residence. 
This suggests that environmental factors have more influence on risk than 
genetic factors.
1.3.5 Diet
Some studies have suggested that high dietary fat intake may increase risk of 
breast cancer and that this may to some extent explain some of the 
geographical differences as more Westernised countries tend to have more 
fat in their diets. There is also some evidence that there is a protective role of 
monounsaturated fats and omega 3 fatty acids. For the most part, the 
relationship between diet and risk is largely inconclusive.
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1.3.6 Weight and weight gain
Several studies have shown that a high body mass index (BMI) in pre 
menopausal years has a protective effect on breast cancer risk, but post 
menopausaliy a high BMI or weight gain can increase risk. One
hypothesis on why this may be so is again related to oestrogen exposure in 
that premenopausal obesity can be related to anovulation and the fact that 
oestrogens are produced in adipose tissue in postmenopausal w o m e n I t  
has never been shown, however, that obese females have higher levels of 
oestrogen.
1.3.7 Smoking and Alcohol
There is no relationship between smoking and breast cancer.^®
Alcohol intake has been shown to have a positive effect on breast cancer risk 
in developed countries. Even after correction for confounding variables such 
as smoking, race, education, family history, use of exogenous hormones and 
reproductive history it may be attributable for about 4% of breast cancers. 
For women who regularly drink alcohol the lifetime risk of breast cancer is 
estimated to increase by approximately 0.7 per 100 women for each unit of 
alcohol consumed per day.
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1.3.8 Genetic Influence
Family history is the most widely recognised risk factor for breast cancer. 
Evidence for genetic predisposition was derived originally from the 
observation of cancer clustering in families. This may be attributed to both 
shared genes and to shared environments and lifestyles. Most studies show 
around a 2 fold risk for women who have a first degree relative affected with 
the disease especially if that relative was premenopausal at the time of 
diagnosis. The risk is less with second degree relatives.
Lichtenstein et al studied the influence of heritable and environmental factors 
on various cancers using registries of Scandinavian twins. They found that 
the effect of heritable factors was statistically significant for breast cancer. 
Their results also supported the general agreement that environmental 
factors are the predominant contributors to the causation of sporadic
cancers/G
There are 5 known gene mutations which predispose to breast cancer. BRCA 
1, BRCA 2, P53, PTEN and ATM. BRCA 1 and 2, which occur on the long arms 
of chromosomes 17 and 13 respectively, can cause a high risk of breast 
cancer and ovarian cancer. Because these genes are so large hundreds of 
mutations can occur which can make detection of a new mutation difficult. 
Mutations in P53 predispose to Li- Fraumeni syndrome which as well as early 
onset breast cancer can cause childhood sarcomas and brain tumours. PTEN 
mutations cause Cowden's disease where breast cancer is a major feature.
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High risk mutations probably account for most families with four or more 
breast cancer cases, for 20-25% of familial breast cancer risk and 4% of all
breast cancers.
In the Scandinavian twin study they found that only a fraction of the genetic 
effects in their population could be explained by the known gene mutations 
described above due to their low frequency. This suggests there are other 
genes yet to be identified.^®
1.3.9 Ionising Radiation
Exposure to ionising radiation increases risk of breast cancer. There is an 
increased incidence of breast cancer in survivors of the atomic bombs in 
Hiroshima and Nagasaki.^^ Women treated with radiation therapy for 
Hodgkins disease also have an increased risk of breast cancer. This risk is 
increased the younger the female was at the time of exposure.
1.3.10 Pollution
There is no firm evidence that exposure to pollutants such as pesticides or 
occupational exposures are related to breast cancer risk. Further studies are 
also being done to assess the effect of electromagnetic fields, for example, 
from mobile phone pylons.
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1.3.11 Benign breast disease
There is an association between some benign breast conditions and cancer. 
Dupont and Page showed a five fold increase in risk with atypical hyperplasia. 
This risk increases to ten fold when there is also a positive family history.
At slightly increased risk are those with moderate or florid hyperplasia, 
papilloma or cysts (1.5- 2 times). Most other benign lesions have no 
increased risk.®^  The usefulness of these findings as population markers is 
limited as lobular or ductal hyperplasia with atypia are only found in 4% of 
breast biopsies and only 15% of women have ever had a breast biopsy.®^
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Factor
Age
Geographical location 
Age at menarche 
Age at menopause 
Age at first full pregnancy 
Family history
Benign breast disease 
Cancer in other breast 
Socioeconomic group 
Diet 
Body weight: 
Premenopausal 
Postmenopausal 
Alcohol consumption 
Ionising radiation exposure
Exogenous hormones: 
OCP 
HRT 
Diethylstilbestrol
Relative risk
>10
5
3
2
3
>=2
4-5
>4
2
1.5
0.7
2
1.3
3
1.24
1.35
2
High risk group
Elderly 
Developed country 
Before 11 
After 54 
First child in early 40s 
First degree relative when 
young 
Atypical hyperplasia
Groups 1 and 2 
High fat intake
BMI>35  
BMI >35  
Excessive intake 
Abnormal exposure in 
young females
Current use 
Use for > =10  yrs 
During pregnancy
Figure 2. Established and probable risk factors for breast cancer. 
Data from McPherson K, Steel CM, Dixon JM. BMJ 321: 624-628. 
2000.
32
1.4
Breast cancer and deprivation
The link between breast cancer incidence, survival and deprivation is well 
established. As can be seen in figure 2 affluent women are more at risk from 
breast cancer than those from more deprived backgrounds by about 2 fold.^^ 
However, women from more deprived backgrounds with breast cancer tend 
to have a poorer outcome in terms of survival and this has been shown to be 
true in numerous studies from different countries. Thomson et al found a 
10% difference in survival at 10 years between affluent and deprived women 
in Scotland.®  ^ Similar results have been found in England, Wales, the US and 
Finland.®"^  The reasons for poorer survival outcomes in women from deprived 
backgrounds remain unclear. Poorer survival outcomes can be seen with 
other types of cancer also, such as colon cancer.
Some studies have shown that women from deprived areas with breast 
cancer have more advanced cancers at presentation either by stage or poorer 
pathological prognostic indicators (e.g. size, nodal status and grade) 
but others disagree. Thomson et al however, not showing any
difference in stage at presentation between affluent and deprived patients, 
did find that patients from more deprived backgrounds had a higher incidence 
of ER negative tumours®  ^ which have a poorer prognosis. This correlates 
with results from an American study which found a positive relationship 
between negative ER status, income and education."^^
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If women from deprived areas are presenting with more advanced disease 
this may suggest that they are less breast aware and are less educated with 
regards to the disease or that fewer are attending for screening. Stage at 
presentation may well partly be to blame for poorer outcome, but cannot be 
the sole reason as some studies have shown poorer outcome with no 
difference in stage at presentation and those that did still showed poorer 
survival outcome in deprived women when corrected for stage of disease.®^ '
A higher incidence of ER negative tumours in women from deprived areas 
again could only partly explain the difference with an estimated 2.2% five 
year survival difference being attributable to this.
The question as to whether there is any treatment difference between the 
affluent and deprived populations, which may make a difference to outcome, 
has been raised and in Scotland this has been looked into. Thomson's 
patient population consisted of 21 751 women diagnosed with breast cancer 
between 1978 and 1987 prior to the introduction of screening and 
standardisation of cancer care in the UK. The study found that women under 
65 with non-metastatic disease were more likely to have breast conservation 
than mastectomy if they were affluent (45%) than deprived (32%), although 
over all age groups there was no difference in the type of surgery between 
deprivation groups. Affluent women were more likely to receive endocrine 
therapy (65%) than deprived (50%). The differences in treatment seen here 
may reflect the higher (but not significant) incidence of larger tumours in 
deprived patients and the higher incidence of ER positive tumours in the
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affluent. Also, because breast conservation is no more effective than 
mastectomy in terms of survivai this difference seen should not affect 
outcome.
A smaller study from the Greater Glasgow Health Board area retrospectively 
reviewed hospital and general practice records of 821 women who lived in 
either affluent or deprived areas and were diagnosed with breast cancer in 
1992/3.^^ Different aspects of treatment and care were examined including -  
type of surgery to the breast and axilla, adjuvant radiotherapy, chemotherapy 
and endocrine therapy and access to care (e.g. delays after presentation). No 
difference was found in access to hospital care, surgical or non-surgical 
management between women from affluent and deprived areas.
As previously mentioned survival rates for breast cancer are improving for 
various reasons including better treatments and increased use of adjuvant 
therapy, more breast awareness, better prognosis tumours being detected at 
screening, and improved delivery of care. A recent Scottish study comparing 
survival in 1987 and 1993 reassuringly showed that survival improvements 
were similar for both the affluent and deprived groups of women.®
In summary, survival differences between women from deprived areas and 
affluent areas with breast cancer cannot be explained in full by differences in 
stage of disease at presentation, incidence of ER negative tumours or be due 
to treatment differences. Other factors suggested which may well be involved 
include -  poorer host responses, co morbidity, adverse nutritional status, less
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social support and negative psychological factors in women from deprived 
areas. At the present time there is littie known about the effects of these on 
breast cancer outcome. They are also factors that would be very difficult to 
change.
It is known that women from affluent areas are better attenders at screening 
from data from the Greater Glasgow Health Board breast-screening 
programme (figure 3). If the attendance at screening of deprived 
populations was improved this would increase detection of better prognosis 
tumours in this group which, in turn, would improve survival. The incidence 
gap between deprived and affluent groups would also be narrowed.
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Percentage of Women attending an invitation for Breast 
Screening,
by Deprivation Category, in 3-year screening cycles. 
Females aged 50 - 64, Scotland
&
□  1990/91 - 1992/93 
■  1993/94 - 1995/96
□  1996/97 - 1998/99
□  1999/2000 - 2001/02
Carstaifs Deprivation Category
Figure 3. Deprivation and screening uptake in Greater Giasgow 
Health Board Area. Data from GGHB breast screening programme. 
Graph from www.isdscot#and.co.uk.
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If the socioeconomic gap in breast cancer survival is to be closed then further 
epidemiological study is required to establish the other possible negative 
factors such as lifestyle and environmental differences. Prevention of the 
occurrence of the known detrimental factors, which have some effect on 
survival such as stage of disease at presentation, is also required, maybe by 
improving education and awareness and improving attendance at screening.
Two studies in Glasgow have looked at deprivation, pathological prognostic 
factors and stage of disease at presentation. Madeod et al found that 
women from deprived areas did have larger more advanced tumours or 
metastatic disease at presentation in a population of 417 women. There was 
no difference in other pathological variables measured (grade, node status). 
This contradicted the study by Carnon et al who found no differences in stage 
or pathology between affluent and deprived in a population of 1361 women. 
In both of these studies substantial amounts of data regarding the tumour 
pathology was unknown. The studies were also done prior to the full 
implementation of the Glasgow breast screening programme.
The main aim of this thesis was to clarify the relationship between 
deprivation and pathological prognostic indicators in the Glasgow area by 
using a bigger sample of patients with almost complete pathological data and 
in a population in whom screening was available. Confirmation of the 
relationship between pathological stage and deprivation should, in turn, spur
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I1
on these possible steps for prevention of improving education and attendance 
at screening in deprived populations.
1.5 
Therapy for Operable Breast Cancer
The treatment for primary operable breast cancer comprises of four 
modalities -  surgery, radiotherapy, chemotherapy and endocrine therapy. 
The aim is to treat the primary tumour, manage the axilla and prevent 
locoregional and distant metastatic disease.
1.5.1 Surgery to the breast
Surgery to the breast can either be by mastectomy or by breast conserving 
surgery. Conservation surgery is normally followed by radiotherapy to the rest 
of the breast tissue. It is well established that conservation surgery and 
radiotherapy are as effective as mastectomy in the treatment of the primary 
tumour in selected cases.
The decision on whether to recommend a mastectomy or breast conservation 
depends on - the size of the tumour in relation to the size of the breast, if the 
tumour is multifocal or close to excision margins, the age of the patient 
(young patients have increased risk of local recurrence), the patients own 
preference and their fitness for surgery/ radiotherapy. Breast reconstruction 
may be possible after mastectomy and is discussed with all patients prior to 
surgery.
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1.5.2 Surgery to the axilla
As yet there is no consensus on the best way of managing the axilia. Excision 
of the axillary contents provides information on nodal métastasés. This aids 
the decision on requirement for further treatment with chemotherapy and 
radiotherapy. It also provides a guide to prognosis (table 1), reduces 
recurrence in the axilla, and may even cure and improve overall survival.
Survival of women with breast 
cancer according to lymph node 
status
Survival of patients according to 
tumour stage
Survival at 10 
years
Stage Survival at 
5years
All patients 45.9% I 84%
Node -ve 64.9% II 71%
Node +ve 24.9% III 48%
1-3 +ve nodes 37.5% IV 18%
>4 +ve nodes 13.4%
Table 1. Patient survival according to lymph node status and stage 
breast cancer. Data from "The ABC of Breast Disease". BMJ 
Publications.
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Surgical procedures performed on the axilla include -  axillary node clearance 
(ANC) level I -  to lateral border of pectoralis minor, level II -  to medial 
border of pectoralis minor, level III -  to the apex of the axilla, axillary node 
sampling (ANS) and sentinel lymph node biopsy (SLNB).
ANC (level III) removes the entire nodal contents of the axilla and is the only 
procedure which fully stages and treats nodal disease. It carries with it 
significant morbidity and therefore the less extensive procedures of ANS 
(removal of at least 4 individual lymph nodes from the lower axilla) and SLNB 
(removal of the nodes most likely to be first in the chain draining the tumour) 
have been performed in an attempt to assess the nodal status of the axilla 
while causing less morbidity especially in women who are unlikely to have 
axillary spread. It has been found that the incidence of nodal métastasés in 
patients with tumours of 10mm or less is low. Some studies of tumours of 
5mm or less have had an incidence of axillary métastasés of 0% and 
some suggest abandoning ANC in these patients. 6^,47,48,49 studies of
tumours up to 10mm have had as many as 27% with positive nodes. At 
the present time level II ANC is the current preferred practise in the West of 
Scotland. In the South East ANS or SLNB is performed for small, well 
differentiated carcinomas.
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1.5.2.1 Morbidity from axillary surgery
Several studies have been done to assess the effect of axillary surgery plus or 
minus radiotherapy (which is given selectively in cases with positive nodes) 
on arm morbidity.
Arm swelling is very common after axillary surgery and often settles after a 
few weeks. Lymphoedema may develop months or even years after surgery. 
Around 75% of cases occur within one year of surgery. The incidence 
reported varies and can be anything from 13-57%. There is often a 
precipitating factor such as venepuncture or infection, for example, after a 
cut. Lymphoedema can also, rarely, lead to secondary lymphangiosarcoma 
(Stewart-Treves syndrome).
Other morbidities reported with axillary surgery include -  reduced shoulder 
mobility, stiffness, pain, numbness and loss of arm strength.
Some have found that these symptoms improve over time but others have 
not.^^ It has been shown that women with post axillary surgery arm morbidity 
also have increased psychological morbidity and reduced quality of life 
associated with it.
Radiotherapy to the axilla along with surgery causes a significant increase in 
morbidity.^®' Ververs et al showed a greater than 3 fold increase in
the risk of lymphoedema when axillary radiotherapy was given after
42
surgery.^® Most would advocate that surgery plus radiotherapy is best 
avoided if possible.
When compared to ANC less extensive surgery to the axilla causes less arm 
morbidity. This has been shown to be true for both ANS and
SLNB.®"^ ' 65
1.5.2.2 Axillary sampling
ANS is the removal of at least 4 lymph nodes from the lower axilla, which are 
detected by palpation by the surgeon at operation. The question of whether 
ANS can be used as an alternative to ANC and provide the same accurate 
staging information, reduce recurrence in axillary nodes and improve survival 
has been looked into in several trials.
Some have found that ANS is not sufficient and suggest that removal of at 
least 10 axillary nodes or complete clearance is required to provide 
the most accurate information and reduce risk of leaving involved nodes 
behind.
A randomised trial of sampling versus clearance after mastectomy by Forrest 
ARM et al followed up patients for a median of 4.1 years. This showed no 
statistically significant difference in disease free survival or in the time to 
axillary or breast cancer recurrence between those who had ANS and those 
who had level III ANC.^ ® The majority of patients who had ANS and were
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found to have positive nodes were, however, given radiotherapy to the axilla, 
which unfortunately increases the morbidity.®®' The Clinical Standards Board 
for Scotland states that at least four nodes must be examined for the axilla to 
be effectively assessed and that over 90% of patients in Scotland having 
axillary surgery for breast cancer should have this adequate axillary surgery.^^
1.5.2.3 Sentinel node biopsy
A possible solution to the dilemma of how to treat the axilla is SLNB. This is 
when the first node or nodes most likely to drain the tumour are identified 
(by dye and or radioactive tracer) and removed. The thinking behind this 
technique is that if the first node in the draining chain does not contain 
tumour then it is unlikely that tumour will have spread to subsequent nodes. 
Multicentre randomised control trials are ongoing and will hopefully provide a 
definitive answer as to whether SLNB can replace ANC. Sentinel node biopsy 
is used successfully in the treatment of malignant melanoma.
Over the last ten years much work has been done to determine whether 
SLNB does indeed provide accurate staging in the axilla in breast cancer. In a 
meta-analysis of 11 trials of patients who had a SLNB followed by ANC the 
sentinel node was identified in 83.6% with a false negative rate of 5.1% 
(when the ANC is positive for metasases but the sentinel node is negative). 
The studies were from surgeons who were experienced in SLNB. It is 
suggested that surgeons should have a false negative rate of less than 5%
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before performing SLNB routinely/^ There is a learning curve with the 
procedure and some centres have reported false negatives of up to 13%
Higher false negative rates may be more acceptable, however, in patients 
with small tumours who are clinically node negative and less likely to have 
axillary spread. An example is given by McMasters et al -  In patients in 
whom the risk of nodal métastasés is generally less than 10 -15% - if the 
false negative rate were 10% only about one such patient in 100 would be 
assigned too low a stage. ADK Hill et al agree that it is in patients with 
early breast cancers that this procedure is most valuable. In one study the 
predictive value in patients with tumours less than 1.5cm was 100% and 
suggested that SLNB should indeed substitute axillary clearance in patients 
with small cancers.
In Britain the ALMANAC (Axillary Lymphatic Mapping Against Nodal Axillary 
Clearance) trial is ongoing. Phase 1 assesses the learning curve with SLNB 
and recent results have shown that with training, after 40 procedures, a 
surgeon can achieve a localisation rate of over 90% with a false negative rate 
of 5% or less.^ ® Once trained to this level the surgeon will move to phase 2. 
This is the randomisation phase comparing SLNB to ANC. Patients with 
positive sentinel nodes will go on to have radiotherapy or completion 
clearance. Those with negative sentinel nodes will be followed up. Primary 
outcomes relate to arm morbidity, quality of life and health economics. Long
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term end points will look at axillary recurrence rates in patients who had no 
further treatment after a negative SLNB.
A secondary aim in this thesis was to assess the incidence of nodal 
métastasés in relation to other pathological prognostic indicators in women 
with early breast cancers of 10mm or less. This was in an attempt to find a 
population of women who would be unlikely to have axillary métastasés and 
therefore provide a target population for either omission of axillary surgery 
altogether or assessment with SLNB.
1.5.3 Other therapies for operable breast cancer
The Early Breast Cancer Trialist's Collaborative Group confirmed that multi 
agent chemotherapy and/ or endocrine therapy (e.g. tamoxifen) and ovarian 
ablation improves disease free survival and overall survival in all age groups.
Almost all patients receive some sort of adjuvant therapy. The need for 
adjuvant systemic therapy is determined by assessing the patients' risk of 
recurrence. This is based on tumour size, ER status, grade, menopausal 
status and most importantly nodal status.
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Present SIGN guidelines suggest the following;
In pre or pen menopausal women
• Women with low risk disease (T1 or 2 node -ve) should be considered for 
endocrine therapy if ER positive.
• Intermediate or high risk (T3 or grade 3, node +ve or -ve), ER positive 
disease should be offered chemotherapy or ovarian ablation.
• Intermediate or high risk, ER negative disease should be offered 
chemotherapy.
In post menopausal women
• Low risk ER positive disease should be considered for endocrine therapy.
• Intermediate or high risk, ER positive disease should be considered for 
endocrine therapy and/ or chemotherapy.
• Intermediate or high risk, ER negative disease should be considered for 
chemotherapy (+/- endocrine therapy) if fit.
Some women with large tumours have neo adjuvant chemotherapy to down
stage their tumour prior to surgery.
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Method
CHAPTER 2
Method
Data has been collected prospectively from five hospitals In the Glasgow area 
since October 1995 and entered onto the Greater Glasgow Health Board audit 
of all operable breast cancers database.
Audit forms have been made available to the breast surgeons in each hospital 
and also to the pathologists dealing with the samples. There are separate 
forms for the clinical and pathological details of each patient (pages 51-52). 
This reduces the risk of patients being missed from the audit as the forms are 
submitted separately. Only patients with operable breast cancers are included 
in the study, as those who have no surgery will have no pathology results 
and the main purpose of the database is to provide data from which 
associations between clinical and pathological findings can be sought.
The database includes all patients with operable breast cancers from Glasgow 
and East Renfrewshire and some screen-detected patients from Lanarkshire 
who were treated in Glasgow.
There are an estimated 219,137 females age 30 and above in Glasgow and 
East Renfrewshire with around 55,381 in the 50-65 screening age group. 
Around 500-600 new breast cancers (operable and inoperable) are diagnosed 
every year in the Greater Glasgow Health Board area."^ ^
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The audit database contained details of 3259 patients who had breast 
cancers operated on between October 1995 and 2001 (around 550 a year). 
This is similar to the numbers recorded by Scottish cancer registries when the 
exclusion of inoperable and the inclusion of screen-detected cancers from out 
with Glasgow are considered.Although there is no way of determining 
exactly how many patients may have been missed from the audit this 
suggests that the dual submission of audit forms has omitted few.
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2.1
Assessment of deprivation and prognostic indicators in all patients 
with operable breast cancer.
The database was utilised and details of all patients with operable breast 
cancers between October 1995 and October 2001 were examined. This 
included both symptomatic and screen detected cancers and patients who 
had been treated by mastectomy or wide local excision and axillary clearance.
2.1.1 Carstairs Index
The deprivation score was calculated according to the Carstairs index of 
deprivation. This is a scoring system that uses census data and corresponds 
to the postcode area where the patient lived at the time of diagnosis.
Vera Carstairs and Russell Morris developed the system in 1981 using the 
1981 census data. It is said to be a measure which reflects access to " those 
goods and services, resources and amenities and have a physical 
environment which are customary in society." It is a measure of relative 
disadvantage between populations within small geographic areas, which, in 
Scotland, can be applied to postcode areas. Each postcode area has a 
population of around 5000.
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The deprivation index takes into account four variables from the census data:
• Overcrowding -  proportion of all persons living in private households 
with a density of more than one person per room.
• Male unemployment -  proportion of economically active males seeking 
or waiting to start work.
• Low social class -  proportion of all private households with 
economically active head with head of household in social class IV or V 
(based on occupation).
• No car -  proportion of all persons in private households who do not 
own a car.
A score is formulated by standardising each of the four variables so that each 
has the same influence. The sum of the standardised variables produces the 
deprivation score (i.e. a measure of socioeconomic status relative to the 
average for Scotland). Deprivation categories which range from 1-7, 1 being 
the most affluent and 7 the most deprived are derived from these scores. 
The intermediate areas contain a mixture of both affluent and deprived 
households. Deprived areas and affluent areas can lie, geographically very 
close to each other, (figure 1).
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Figure 1. Sherbrooke Avenue, Poliokshicsids is affluent according to 
the Carstairs index. Half a mile down the road are the high rise flats 
on Broomioan Road, Ibrox. Deprivation category 7.
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In Scotland 62% of the population are in Intermediate areas (deprivation 
categories 3,4 and 5). Glasgow, however, has a high proportion of deprived 
households with 30% of the population in the most deprived 7% of the 
Scottish population.®^  (Figure 2)
percentage 
of the 
Scottish 
population
I I Greater Glasgow NHS Board 
Rest of Scotland
affluent
areas deprivation score
deprived
areas
Figure 2. Comparison of deprivation scores between Greater 
Giasgow NHS Board area and the rest of Scotland. (Graph from  
Carstairs scores for Scottish postcode sectors from the 2001 census. 
P McLoone. March 2004)
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The scoring system of 1981 has been updated for the 1991 census and again 
for the 2001 census by Philip McLoone. This shows little change in scores in 
Scotland between 1981 and 1991 and 2001 although some areas have 
changed deprivation category. Those areas that did tended to be ones with 
smaller populations where the data is not so robust.®  ^ In this study the 1991 
deprivation scores were used.
As described in the Scottish economic report of July 2000 the use of the 
Carstairs index does have its limitations:
Postcode areas are not homogenous and some areas contain a mix of 
affluent and deprived households and therefore depending on the population 
of the area some intermediate areas may actually contain more deprived 
households than a deprived area. Urban areas such as Glasgow, however, 
tend to be more homogenous.
The choice of indicators from the census is arbitrary and equal weight is 
given to each. For example car ownership in rural areas where a car is a 
necessity may not be as useful an indicator of deprivation as in urban areas. 
Equally, in this day and age, many affluent people choose to live in city 
centre apartments close to their place of work negating the need for a car. 
Census data is only updated every ten years, which may cause problems in 
monitoring health inequalities over this time period.
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Despite Its limitations McLoone has shown the index to correlate with other 
socio-economic indicators and to be a good indicator of all cause mortality. 
Postcode information is the only indicator of socio-economic status on a 
patient's case record and thus the Carstairs index has been used effectively in 
many studies of deprivation and health.
In this study we separated patients into three groups. Affluent - deprivation 
categories 1 and 2, intermediate - categories 3, 4 and 5 and deprived -  
categories 6 and 7.
2.1.2 Database information
The information extracted from the database included:
Hospital details 
Patient unit number 
Patient date of birth 
Date of surgery 
Mode of presentation 
Tumour- Size
Histological grade 
Oestrogen receptor (ER) status 
Oestrogen receptor percentage 
Number of nodes excised 
Number of nodes involved
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The patient date of birth and date of surgery details were used to calculate 
whether the patient was of screening age at the time of diagnosis and this 
was related to their mode of presentation. Mode of presentation included 
symptomatic, screened, symptomatic/ previously screened (i.e. interval 
cancers) and mammographlcally detected but not a screening mammogram. 
Size was measured in millimetres and was either the gross or histological 
measurement. Tumours were graded 1,2 or 3 according to the Bloom and 
Richardson grading system. Size, grade and nodal status were used to 
calculate the Nottingham Prognostic Index (NPI) for each patient.
The relationship between deprivation and tumour size, grade, ER status, 
Nodal status and NPI were examined. For some of the patients the data was 
incomplete. As much of this missing data as possible was recovered by 
reviewing the case notes and pathology records. When the ER status or 
percentage result was missing the pathology slides were re examined. (Figure 
3a and 3b)
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rFigure 3a. ER positive breast cancer. ER receptor positive ceils stain 
brown.
%
g
Figure 3b. ER negative tumour. No brown stain.
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The variables were examined both with and without the exclusion of patients 
who had less than four lymph nodes assessed (as it was assumed they may 
not have had their axillae accurately assessed) or any other missing data.
2.2
Assessment of deprivation and prognostic indicators in tumours of 
10mm or less
The database was utilised and the details of patients who had breast cancers 
of 10mm or less excised and who had deprivation details available between 
October 1995 and March 2001 extracted. This included patients who were 
both symptomatic and screen detected. Patients who had less than four 
nodes excised were excluded from this part of the study as it was assumed 
that these patients might not have had their axillae accurately assessed.
The effect of deprivation on the above pathological variables was assessed 
again for this group to see if the findings would be similar even for patients 
with early cancers. The effect of deprivation on the presence of 
lymphovascular invasion (LVI) was also looked at. Lymphovascular invasion 
was defined as invasion of lymphatic and/ or blood vessels.
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2.3
Assessment of pathological prognostic indicators In patients with 
tumours of 10mm or less.
Once again the details of patients with tumours of 10mm or less was 
examined. All those with tumours excised between October 1995 and March 
2001 were included. The relationship between size, grade, ER status, LVI and 
the presence of lymph node métastasés was examined in an attempt to see if 
there was a particular subgroup of patients with small tumours who are 
unlikely to have axillary involvement. All patients with less than four nodes 
excised were excluded.
2.4
Statistical analysis.
Univariate analysis was carried out on each of the variables using the Chi- 
square test. The Mann-Whitney U test was also applied to nodal métastasés 
in relation to size as it was also assessed as a continuous variable. A 
multivariate analysis was carried out when assessing the pathological 
prognostic indicators in early breast cancers using logistic regression (forward 
stepwise selection).
Statistics were calculated using SPSS for Windows.
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CHAPTER 3
Assessment of deprivation and prognostic Indicators In all patients 
with operable breast cancer.
3.1
Introduction
The main aim of this thesis was to clarify the relationship between 
deprivation and pathological prognostic indicators in the Glasgow area by 
using almost complete pathological data from a large population in whom 
screening was available. Confirmation of a relationship between pathological 
stage at presentation and deprivation should, in turn, spur on possible steps 
for prevention of improving education and attendance at screening in 
deprived populations. Other aspects of tumour pathology such as grade and 
ER status are also assessed in this study to see if women from deprived areas 
are more likely to have more aggressive tumours.
3.2
Results
There were a total of 3251 patients in who deprivation details were available 
between October 1995 and October 2001. 598 affluent, 1473 intermediate 
and 1180 in the deprived group. Deprivation details were missing for 8 
patients.
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Size was not recorded for 4 intermediate and 9 deprived patients.
Patients in the deprived group were significantly more likely to have larger 
tumours at operation with 33.3% of affluent, 35.6% of intermediate and 
43.4% of deprived having tumours of greater than 20mm (p<0.001). (Table 
1).
Grade was not available for 9 affluent, 10 intermediate and 8 deprived 
patients.
The incidence of grade 3 tumours in the deprived group was significantly 
higher in the more deprived patients. 35% of deprived patients had grade 3 
tumours. 30% and 27% of intermediate and affluent patients had grade 3 
tumours respectively (p<0.002). (Table 2).
ER status was not recorded for 9 affluent, 15 intermediate and 15 deprived 
patients.
There was a trend for the more deprived patients to have a higher incidence 
of ER negative tumours (p=0.016).
When the ER positive tumours were divided into groups according to ER 
percentage the deprived patients were less likely to have highly positive 
tumours (p<0.01). (Table 3).
Patients who had less than 4 nodes excised were not included when looking 
at node status as it was assumed that they might not have had their axilla 
accurately assessed. This totalled 126 patients. (24 affluent, 50 intermediate 
and 52 deprived).
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The deprived had a significantly higher incidence of node positive tumours 
(p=0.043). 36.8% of affluent, 40.7% intermediate and 42.1% of deprived 
patients were node positive. (Table 4).
NPI was calculated for all patients in who size, grade and nodal status was 
available.
Deprived patients had significantly higher NPIs reflecting the higher incidence 
of larger, grade 3 tumours in this group (p<0.001). 45.9% of affluent, 41% 
of intermediate and 35%of deprived were in the low risk NPI group. (Table 
5).
The other variables were examined again excluding patients who had less 
than 4 nodes examined or any other missing data as for NPI and the 
significant variables were still found to be so except with node positivity.
From the total of 3251 patients 1685 were in the 50-65 year screening age 
group (309 affluent, 807 intermediate and 569 deprived patients). Out of this 
group 60.2% of affluent, 65.5% of intermediate and 56.9% of deprived 
patients were either screen detected or presented with interval cancers 
(2.6%, 2.1% and 2.8% of affluent, intermediate and deprived respectively). 
Significantly less deprived patients were screen detected (P<0.01).
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Table 1
Size and Deprivation
Size Affluent Intermediate Deprived
1-lOmm 152 (25.4%) 317 (21.6%) 200 (17.1%)
ll-20mm 247 (41.3%) 629 (42.8%) 463 (39.5%)
21-50mm 188 (31.5%) 483 (32.9%) 471 (40.2%)
>50mm 11 (1.8%) 40 (2.7%) 37 (3.2%)
P<0.001
Figure 1.
Size and deprivation
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Table 2
Histological Grade and Deprivation
Grade Affluent Intermediate Deprived
1 151 (26%) 344 (23%) 265 (23%)
2 277 (47%) 684 (47%) 493 (42%)
3 161 (27%) 435 (30%) 414 (35%)
P <0.002
Figure 2
Grade and deprivation
12 35
W 25
■  Grade 1
■  Grade 2 
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Tables
ER Status and Deprivation
ER Status Affluent Intermediate Deprived
ER-ve 111 (18.8%) 320 (21.9%) 279 (24%)
5-24% 22 (3.7%) 71 (4.9%) 56 (4.8%)
25-49% 31 (5.3%) 45 (3.1%) 46 (3.9%)
>=50% 425 (72.2%) 1022 (70.1%) 784 (67.3%)
P <0.01
Figure 3
ER Status and deprivation
B R -ve 5-24%  2M 9P /0  >=60%
EFt status
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Tabled
Node Status and Deprivation
Affluent Intermediate Deprived
Number 574 1423 1128
Node +ve 211 (36.8%) 579 (40.7%) 475 (42.1%)
P =0.043
Figure 4
Node Status and deprivation
n% node
Affluent Intermediate Deprived
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Table 5
NPI and Deprivation
Affluent Intermediate Deprived
Number 567 1410 1115
<=3.4 
Low risk
260 (45.9%) 578 (41%) 391 (35%)
3.41-5.4 
Med risk
221 (39%) 613 (43.5%) 528 (47.4%)
>5.4 
High risk
86 (15.1%) 219 (15.5%) 196 (17.6%)
P<0.001
Figure 5
NPI and deprivation
Afluert IntermBciatB Dspmed
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3.3 
Discussion
It is well established that affluent women have a higher incidence of breast 
cancer than women from deprived areas however women from 
socioeconomically deprived areas have a significantly poorer survival from 
breast cancer than women from affluent areas.
This study has found that the poorer outcome of breast cancer patients from 
deprived areas is multifactorial. Significantly fewer patients from deprived 
areas have screen-detected tumours and as there is no increase in the 
interval cancers in this group then this implies that fewer women from 
deprived areas attend for screening. This would agree with the results from 
the Greater Glasgow Health Board Breast Screening service data described in 
chapter 1. Poorer attendance at screening results in deprived patients having 
significantly larger tumours at operation, which is what this study has 
confirmed.
However, other factors also contribute to the poorer outcome; women from 
deprived areas have significantly more high grade tumours and they are also 
more likely to have ER negative tumours which may be secondary to 
environmental factors, impaired host responses and co-morbidity. Although 
deprived patients do not have a significantly higher incidence of node
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positivity the differences In size and grade were sufficient to produce a 
significantly poorer prognosis according to NPL
This study has demonstrated different results to a previously mentioned study 
from Glasgow looking at the relationship between socioeconomic factors and 
pathological prognostic factors. The reasons for this are easily explained.
In the study by Carnon only 1361 patients were assessed of which Grade 
was only recorded in 54% of patients (99.2% in this study), and oestrogen 
receptor status in 69%, which although low was high for the time period in 
question, of patients (98.8% in this study). In their study lymph node status 
was not recorded in 46% of patients compared to 3.9% in this study and this 
may have resulted in women being under staged and so under treated.
Similarly, in McLeod's study of 417 patients , grade was recorded in 72.7%, 
size in 90.2% and node status in 88.5% which again is far less than in this 
study.
Bias is unlikely in this study because it is a population based, prospective 
audit with high numbers in each of the deprivation groups. A very small 
percentage of data was unavailable and similar proportions were missing 
from each group.
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To improve breast cancer survival in patients from deprived areas several 
areas need to be targeted. Firstly we need to increase breast awareness in 
patients from deprived areas so that they present earlier but more research is 
needed to determine the factors leading to the development of the more 
aggressive grade three, ER negative tumours in these patients.
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Chapter 4
Assessment of deprivation and pathological prognostic indicators in 
tumours of 10mm or less.
4.1
Introduction
The remainder of the study was aimed at women with early breast cancers of 
10mm or less. These tumours are less likely to have nodal métastasés than 
larger tumours and generally have a better prognosis. It is these women with 
early breast cancers that screening aims to detect. The purpose of this 
section was to assess whether the relationship between deprivation, grade 
and ER status still existed in women with early breast cancers. Additionally, 
the relationship between iymphovascuiar invasion (LVI) and deprivation was 
looked at.
4.2
Results
In total there were 666 patients. We excluded those who had less than 4 
axillary nodes excised. It was assumed that some of these patients might not 
have had their axillae accurately assessed- Those with ungraded tumours 
were also excluded. They were ungraded either because they were not ductal 
tumours or there was too little tissue to assess.
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There were 613 patients after exclusions. Deprivation score was available for 
608 of the patients. 135 affluent, 293 intermediate and 180 deprived.
We found that patients in the deprived group were significantly more likely to 
have higher grade tumours (table 1) with 11.1% of affluent, 15.4% of 
intermediate and 21.7% of deprived patients having grade 3 tumours (p= 
0.032). Grade results were available for ail included patients.
There was a trend for the more deprived patients to have a higher incidence 
of ER negative tumours (table 2) with 11.1%, 17.9% and 19.3% of patients 
in the affluent, intermediate and deprived groups having a negative ER status 
respectively. This however was not significant (p= 0.073). ER status results 
were not recorded for 8 patients (2 affluent, 2 intermediate and 4 deprived).
More patients in the deprived group had Iymphovascuiar invasion present 
(table 3), 13.9% compared to 10.6% and 10.4% in the intermediate and 
affluent groups (p= 0.3), which reflects the higher incidence of grade 3 
tumours. Iymphovascuiar invasion results were available for all patients.
There was no relationship between node positivity and deprivation (p=0.9) 
(table 4), nor was there any significant difference in NPl between the groups 
(p=0.3) although a higher proportion of the affluent group had a low risk NPl 
(table 5).
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Table 1
Grade and Deprivation
Grade Affluent Intermediate Deprived
1 69 (51.1%) 138 (47.1%) 79 (43.9%)
2 51 (37.8%) 110 (37.5%) 62 (34.4%)
3 15 (11.1%) 54 (15.4%) 33 (21.7%)
P = 0.032
Figure 1
Grade and deprivation (T l)
60
50
a 40c
sm 30a.
20
10
0
i  iàÆW
Affluent fenteimediate Deprived
■  Grade 1
■  Grade 2 
□  Grade 3
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Table 2
ER Status and Deprivation
Affluent Intermediate Deprived
Number 132 291 176
ER-ve 15 (11.1%) 52 (17.9%) 34 (19.3%)
P = 0.073
Figure 2
ER status and deprivation(Tl)
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Tables
LVI and Deprivation
Affluent Intermediate Deprived
Number 135 293 180
LVI +ve 14 (10.4%) 31 (10.6%) 25 (13.9%)
P = 0.302
Figure 3
LVI and deprivation (T l)
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Table 4
Node Status and Deprivation
Affluent Intermediate Deprived
Number 135 293 180
Node +ve 23 (17%) 54 (18.4%) 33 (18.3%)
P = 0.937
Figure 4
Node status and deprivation (Tl)
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Tables
NPl and Deprivation
NPl Affluent Intermediate Deprived
<=3.4  
(low risk)
106 (78.5%) 224 (76.5%) 126 (70%)
3.41 -  5.4 
(med. risk)
25 (18.5%) 63 (21.5%) 49 (27.2%)
> 5.4 
(high risk)
4(3% ) 6(2% ) 5 (2.8%)
P = 0.352
Figure 5
NPl and deprivation (Tl)
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4.3
Discussion
It would appear that early breast cancers In women from deprived areas are 
less favourable. The relationship between deprivation and grade remains with 
significantly more deprived women having grade 3 tumours. They also had 
increased incidences of ER negative tumours and iymphovascuiar invasion 
(reflecting the increased number of grade 3 tumours) although this was not 
significant. As with the more deprived group of women as a whole, there was 
no significant increase in nodal spread. Unlike the women from deprived 
areas with tumours of ail sizes, the women with early cancers are not at 
significantly more risk according to NPl than women from affluent or 
intermediate areas.
Again, in this part of the study, bias is unlikely due to the small numbers with 
missing data and similar proportions missing in each group. As the patients 
with known tumours of 10mm or less only were looked at, it is impossible to 
say in how many patients with these small cancers size was not recorded. 
There were only 13 patients in the whole 3259 in the last chapter with size 
not recorded. Therefore, it is likely that the number with tumours of 10mm or 
less in whom size was not recorded are few with little impact on results.
This, as in chapter 3, suggest that we need to increase breast awareness in 
deprived populations so that they present earlier when their risk is not 
significantly different to that of women from affluent and intermediate areas.
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Chapter 5
Assessment of pathological prognostic indicators in patients with 
tumours of 10mm or less.
5.1
Introduction
The aim of this part of the study was to find a population in whom axillary 
clearance could be avoided. Axillary clearance provides information for 
staging and prognosis and may also provide local control and even cure as 
well as aiding in the decision to give adjuvant treatment. However, it carries 
with it significant morbidity such as lymphoedema, paraesthesia and reduced 
shoulder mobility. This can have a negative psychological effect on the 
patient and affect quality of iife.^ '^
It has been found in other studies that the incidence of nodal métastasés in 
patients with tumours of 10mm or less is low. Some studies of tumours of 
5mm or less have had an Incidence of axillary métastasés of 0% and 
some suggest abandoning axillary clearance in these patients.^ '^^^ Other 
studies of tumours up to 10mm have had as many as 27% with positive 
nodes.
Recently much work has been done into the role of sentinel node biopsy as a 
means of assessing the axilla for métastasés, but there is still a false negative 
result of up to 13% with this procedure.^ '^ It has been found that
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sentinel node biopsy is more effective in patients at iow risk of axillary 
spread. Sentinel node biopsy is also associated with less arm
morbidity.^" '^
We wanted to find out which patients with small tumours were least likely to 
have nodal spread and therefore be spared axillary clearance or provide a 
target population for assessment with sentinel node biopsy. From the results 
from chapter 4 it is apparent that deprivation is not a prognostic indicator 
when it comes to incidence of nodal métastasés and therefore it is not 
included in this section.
5.2 
Results
The same 666 patients as in chapter 4 were assessed and again those with 
less than 4 nodes excised or ungraded tumours were excluded. There was a 
total of 613 patients after exclusions. 395 (64%) were screen detected. The 
majority, 461, were ductal carcinomas. The rest were 36 lobular, 88 tubular, 
2 medullary, 10 mucoid, 4 cribriform, 7 mixed and 5 other (e.g. phylloides). 
No distinction between types of tumour was made in this study.
Of the 613 patients 26 (4%) had only 4 nodes examined. That is 4% of the 
patients had axillary sampling rather than clearance. In one of these patients 
all 4 nodes were positive suggesting some diseased nodes may have been 
left behind.
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In total 111 (18.1%) of the patients had positive nodes. Of these, 49 (44%) 
had only one positive node. 19 (17%) had two positive nodes, 10 (9%) had 
three and 33 (30%) had four or more nodes positive.
There was a trend for the larger size tumour to have an increased incidence 
of positive nodes with 13.4% of Tla and 19.2% of T ib  tumours being node 
positive. This difference was not significant (p= 0.18), but when we looked at 
size as a continuous variable it was a significant indicator of nodal spread (p< 
0.001). (Table 1).
A higher grade was also a significant indicator of nodal spread with 11.4% of 
grade 1, 21% of grade 2 and 31.3% of grade 3 tumours having positive 
nodes (p< 0.001). (Table 2)
We looked at the influence of size within each grade and as can be seen in 
the table 3 the trend for the larger size tumours to be more likeiy to have 
métastasés is stiil there in grades 1 and 2, but not for the grade 3 tumours. 
This finding is most likely because of the smaller numbers in this group with 
only 16.2% of patients having grade 3 tumours. (Table 3)
The most important indicator of lymph node spread was the presence of 
Iymphovascuiar invasion (p<0.001). 54.3% of tumours where iymphovascuiar 
invasion was present were node positive. (Table 4)
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The influence of Iymphovascuiar invasion within each grade was aiso 
examined. There was a higher incidence of positive nodes when 
Iymphovascuiar invasion was present and this was true for each grade. It was 
not significant in the grade 3 group and again this is most likely because of 
the smaller number In this group. (Table 5)
When we looked at ER status, as a single variable, those with ER negative 
tumours were significantly more likely to have axillary métastasés than those 
with ER positive tumours (p=0.038). 16.5% of ER positive tumours and 
25.7% of ER negative tumours were node positive. (Table 6) ER status was 
unrecorded for 8 patients.
However, when we corrected the ER status for the other three variables with 
a multivariate analysis it was no longer a significant factor. (Table 7)
The most important predicting indicator was Iymphovascuiar invasion with a 
greater than five fold increase in risk of having positive nodes if 
iymphovascuiar invasion was present. Next was grade with a relative risk of 
1.51 for each step up in grade and then size with a relative risk of 1.15 for 
each millimetre increase in size.
Low risk tumours are those of grade 1 without iymphovascuiar invasion. In 
total 9.5% of grade 1 tumours without Iymphovascuiar invasion of 10mm or 
less were node positive. Of those 5mm or less 5.7% was node positive. None 
of the patients with grade 1 tumours of less than 5mm without
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Iymphovascuiar invasion had axillary métastasés, although the number in this 
group was very small. (Table 8)
Table 1
Métastasés and size.
Total T la Tib
Number 613 119 (19.4%) 494 (80.6%)
Node positive 111 (18.1%) 16 (13.4%) 95 (19.2%)
P= 0.18. Size as a continuous variable P< 0.001
Figure 1
Métastasés and size (T l)
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Table 2
Métastasés and Grade
Grade 1 2 3
Number 289 (4.1%) 225 (36.7%) 99 (16.2%)
Node +ve 33 (11.4%) 47 (21%) 31 (31.3%)
P< 0.001
Figure 2
Métastasés and Grade (T l)
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Table 3
Métastasés, Size and Grade
G rade 1 Grade 2 Grade 3
Size Tla T lb Tla T lb Tla T lb
Node +ve % 5.7 12.7 11.1 23.3 40.9 29.5
P= 0.002 P< 0.001 P= 0.227
Table 4
Métastasés and Lymphovascular invasion (LVI)
LVI -ve LVI +ve
Number 543 (88.6%) 70 (11.4%)
Node +ve 73 (13.4%) 38 (54.3%)
P< 0.001
Figure 4
Métastasés and LVI (T l)
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Table 5
Métastasés LVI and Grade
Grade 1 Grade 2 Grade 3
LVI -ve +ve -ve +ve -ve +ve
Node +ve % 9.5 50 14.6 69.2 26 43.3
P< 0.001 P< 0.001 P= 0.103
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Table 6
Métastasés and ER status
ER +ve ER -ve
Number 504 (83.3%) 101 (16.7%)
Node +ve 83 (16.5%) 26 (25.7%)
P= 0.038
Figure 6
Métastasés and ER status (Tl)
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Table 7
Significant Variables (multivariate analysis)
Relative Risk 95% Cl Significance
LVI 5.4 3.07 -  9.48 P< 0.0001
Grade 1.51 1.12-2.05 P= 0.007
Size 1.15 1.03-1.29 P= 0.01
Table 8
Low Risk Tumours (grade 1, LVI -ve )
Size < = 10mm < = 5mm < 5mm
Number 275 53 20
Node +ve 26 (9.5%) 3 (5.7%) 0
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5.3
Discussion
It is weli recognised that axiliary dissection, especialiy when coupled with 
radiotherapy, causes significant arm morbidity.
Over the years many studies have been performed in an attempt to find a 
way to reduce arm morbidity by means of reducing the extent of surgery to 
the axilla. Some would favour omitting axiliary surgery aitogether in patients 
with breast cancers of 5mm or iess. This study has shown an incidence of 
nodal métastasés in tumours 5mm or iess of 13%. Cleariy omission of axiilary 
clearance cannot be decided on tumour size alone. This has shown that the 
risk of nodai métastasés is multifactoriai with the presence of LVI being the 
most important predictor next to tumour grade.
Size was a less important predictor being significant only as a continuous 
variable and not when divided into Tla and T lb  groupings suggesting that 
choosing a cut off for surgery at 5mm on its own may be meaningless. None 
of the variables assessed in this study alone could accurately predict nodal 
spread. Only a very small subgroup of 20/613 patients with iow risk tumours 
(grade 1, LVI negative, less than 5mm) who were all node negative could be 
identified. Certainly, these patients are unlikely to have axillary disease, but 
for them to avoid axiliary dissection the procedure for all early breast cancers 
would have to be two stage to identify this small group of patients. The
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primary tumour would have to be excised to assess pathology. Once this was 
known the axilla would have to be dealt with appropriately requiring a second 
anaesthetic. This is because assessing grade or presence of LVI can be very 
difficult from core biopsy alone.
This study suggests that there are no patient subgroups in whom axiliary 
surgery can be omitted safely on the basis of the tumour pathological 
predictive factors described.
Lymph node status is an important predictor of survival outcome even in 
cancers of 1cm or less. Axillary node status needs accurate assessment not 
only to aid in the prediction of survival outcome, but also to assist in the 
decision to give adjuvant therapy, which should be considered for all patients 
with positive nodes no matter how big the tumour.
It is possible that axiilary clearance could be avoided in patients with early 
breast cancer if the node status could accurately be predicted by other means 
such as sentinel lymph node biopsy (SLNB). In some areas in the world this 
procedure is being performed almost routinely despite the fact that there are 
no results for randomised controlled trials or with regards to long-term 
outcome.
There is a learning curve associated with SLNB and with it can be a significant 
false negative rate. Higher false negative rates may be more acceptable,
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however, in patients with smail tumours. Furthermore according to Weiser et 
a! patients with tumours of 1cm or iess without LVI who are found to have 
micrometastases in the sentinel node have a iow risk of non sentinel node 
métastasés and therefore may not require completion clearance.
In summary, the results would suggest that axiliary surgery should not be 
omitted even in patients with very low risk cancers. These patients may 
provide a population whose axillae are best assessed by SLNB.
As in the previous chapter, bias is unlikely due to the completeness of the 
data. Because this study looked only at cancers which had been operated on 
and size was measured as the pathological size it is impossible to say from 
this audit if any patients with smail tumours had distant métastasés and did 
not undergo operation.
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General Discussion
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Chapter 6 
General Discussion
Over the past few decades the incidence of breast cancer in Britain and the 
rest of the world has been increasing. Despite this, survival has been 
improving due to improved treatments, better delivery of care and the 
introduction of screening which has served to identify women in the high risk 
age groups with disease at its early stage.
Research has shown that there is no one cause of breast cancer, but that 
there are many risk factors which, in combination, may make some women 
more prone to the disease. Environmental factors probably play a huge role 
and are most likely responsible for the difference in incidence of breast 
cancer seen in different areas in the world.
A similar effect can be seen between women from different backgrounds 
within the same country or even the same city. Women from affluent 
backgrounds have a higher risk of breast cancer than those from deprived 
areas. This could be due to them having different genetic backgrounds and 
environments as well as more risk factors, for example, more may stay longer 
in education and have families later or differences in diet. It is unlikely that 
the reasons for this difference in risk will be easy to identify and even more 
difficult to change.
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Even though affluent women are more at risk of the disease, women from 
deprived areas are more likely to die from it. This study has shown that in the 
Glasgow area women from deprived backgrounds are more likely to have 
bigger, more aggressive tumours at presentation, which in turn, leads them 
to have a poorer prognosis according to NPI. They are also more likely to 
have ER negative tumours which can be more difficult to treat as they do not 
respond to hormone therapy and carry a poorer prognosis.
The findings in this study may certainly explain, to some extent, why these 
women have a poorer outcome. What is not clear is why women from 
deprived areas should have these more aggressive tumours. Again, the 
reasons are almost certainly multifactorial. Genetic as well as lifestyle 
differences and a higher incidence of co-morbidity leading to impaired host 
responses are likely to play a role. Environmental factors such as pollution 
and radiation as well as other as yet unidentified factors may contribute but 
this has not been proven. It is difficult, however, on driving through Glasgow 
not to notice how close in proximity some deprived areas can be to affluent 
areas. They may be only a few hundred meters apart. What environmental 
factor can affect one of those areas and not the other?
It is obvious that further epidemiological research on a huge scale will be 
required if an answer to the socioeconomic differences in breast cancer is to 
be found.
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The improvement in breast cancer survival is seen in both affluent and 
deprived women and probably reflects the standardisation of care over all 
areas. The outcome gap between affluent and deprived still exists and as it is 
likely that this is mainly due to unknown factors out with our control then we 
can only narrow the gap by attempting to improve on factors which we do 
know about. These are the factors described in this study.
Differences in grade and ER status between affluent and deprived again 
cannot be explained easily. The fact that women from deprived areas have 
larger tumours at presentation, as found in this study, and that there was no 
difference in incidence of interval cancers in this population suggests that 
fewer deprived women are attending for screening. This would agree with 
figures from the Glasgow Breast Screening Programme (chapter 1, figure 3). 
It is this area, therefore, which initially should be targeted to try and reduce 
the survival differences between affluent and deprived. It has also been 
shown in this study that deprived women with early breast cancers are not at 
significantly higher risk according to NPI than other women. Thus if they are 
managed early survival differences should narrow further.
To improve attendance at screening, amongst other things, will require better 
education with regards to the service and breast awareness as well as 
encouragement from general practitioners. Recently there has been a 
television campaign warning people of the signs of colorectal cancer. As 
breast cancer is the most common cancer in women should this too be
100
advertised more widely on the media with regards to the Importance of 
attending screening?
The second part of this study focused on women with early breast cancers 
who are those most often picked up at screening. Many of these women do 
not have axillary métastasés and undergo axillary clearance, which for many 
of them will turn out to have been unnecessary and lead to morbidity.
Recently many studies have iooked into the possibility of using sentinel node 
biopsy as a method of assessing the axilla. After training in the procedure it 
can be performed very accurately with low false negative results especially in 
women at low risk of axillary métastasés.
From this study it can be seen that even women with small tumours of 10mm 
or less can have axillary disease aithough the incidence is reasonably low 
(18%). There is not a population of women in whom it could be risked to 
omit axillary surgery altogether. It would seem, however, that these women 
with small tumours could provide a target population for assessment of their 
axilla by SLNB especially if the tumour is negative for LVI, which is the most 
important predictor of axillary spread. 44% of women in this study who had 
positive nodes only had one node with métastasés. The chances are that this 
would be the sentinel node which would be removed at the procedure thus 
potentially it could also cure. There are ongoing studies attempting to find 
accurate predictors of non-sentinei node spread if the sentinel node is
101
positive to try and avoid the need for completion clearance or radiotherapy in 
these patients. Since there are no single accurate predictors of axillary spread 
itself, it seems unlikely there will be one factor that could predict spread to 
non-sentinel nodes.
There are no long term outcome results for the procedure as yet and results 
of randomised controlled trials such as the ALMANAC trial are awaited. SLNB 
is performed routinely in many countries. In Britain the procedure is only 
performed as part of a trail at the present time. It looks promising that in the 
near future this will be the procedure of choice for trained breast surgeons 
here for women with small cancers.
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